CIDP
Business Services · Romania · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Strada Albac nr. 15, Bucharest, Bucurest...Phone Number
+40 317181182Website
www.cidp-cro.comRevenue
$6.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CIDP
CIDP is an international Contract Research Organisation (CRO) established in 2004, specializing in high-performance research and development activities for the pharmaceutical, medical device, nutraceutical, and cosmetic industries. The company offers a full range of services including preclinical and clinical research, biostatistics, regulatory support, and medical writing. With a presence in Brazil, India, Romania, and Mauritius, CIDP is well-equipped to manage clinical trials and generate high-quality data. Their diverse team and strategic locations enable them to cater to a wide array of clients and conduct studies on multiethnic panels.Explore more
CIDP Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CIDP your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if CIDP is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CIDP, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CIDP recently announced quarterly report
Funding: Get notified immidiatlly once CIDP has new funding data
Website visits: Recent activity has been detected on your website
Click to see if CIDP had a recent Job posting/layoffs
Check if CIDP has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when CIDP launches new products
Congratulate Masked Content for being promoted to Masked Content at CIDP
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
CIDP is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CIDP is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CIDP.
CIDP Tech Stack
A closer look at the technologies used by CIDP
See more technologies
CIDP News & Media
Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC injection. The approval is for its use as a monotherapy in adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy/CIDP who have previously been […]Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been dosed in the Greater China portion of the global registrational ADHERE study of efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
TOKYO, March 26, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy ...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding CIDP
Sign Up For FreeTo access detailed company insights
CIDP is an international Contract Research Organisation (CRO) established in 2004, specializing in high-performance research and development activities for the pharmaceutical, medical device, nutraceutical, and cosmetic industries. The company offers a full range of services including preclinical and clinical research, biostatistics, regulatory sup... Read More
